Sarah Owen

The Government is committed to putting patients first. This means making sure that patients are seen on time and ensuring that people have the best possible experience during their care.

We have made a commitment that 92% of patients should wait no longer than 18 weeks from Referral to Treatment within our first term. This includes those waiting for treatment for coeliac disease. As a first step to achieving this, following the Budget, we will deliver an additional two million operations, scans, and appointments across all specialities during our first year in Government, which is equivalent to 40,000 per week.

The Royal College of General Practitioners has an e-learning module on the diagnosis and management of coeliac disease and its immunological comorbidities, which is designed to raise awareness and understanding of the symptoms of coeliac disease amongst general practitioners and primary care professionals and support early diagnosis. The e-learning module highlights that untreated coeliac disease can have important consequences, including small bowel lymphoma and osteoporosis.

The NHS website is also a key awareness tool and contains useful information for the public about coeliac disease, its symptoms and how it is diagnosed and treated. This information is available at the following link:

https://www.nhs.uk/conditions/coeliac-disease/

The National Institute for Health and Care Excellence has guidance on the recognition, assessment and management of coeliac disease, which is available at the following link:

https://www.nice.org.uk/guidance/ng20

The guidance outlines a number of symptoms which are suggestive of coeliac disease and suggests that any person with these symptoms should be offered serological testing for coeliac disease. The guidance also states that first-degree relatives of people with coeliac disease should also be offered serological testing.

The Government’s response to the targeted consultation on proposed changes to the availability of puberty blockers was published on 11 December 2024, and details the individuals and organisations with which the Commission on Human Medicines consulted. It is available at the following link:

https://www.gov.uk/government/consultations/proposed-changes-to-the-availability-of-puberty-blockers-for-under-18s/outcome/9702c8a7-3299-4a01-94dc-a63861786dd9

NHS England commissions gender services for children and young people in line with its interim service specification for children and young people with gender incongruence.

Children and young people are cared for holistically by specialist multi-disciplinary teams based in specialist children's hospitals. The multi-disciplinary team should include expertise in paediatrics, psychological health, and neurodevelopmental conditions.

Each child or young person will have a tailored individual care plan to meet their needs. Depending on individual need, the gender service for children and young people will provide psychosocial and clinical interventions, including support for the family. Further information from the interim service specification is available at the following link:

https://www.england.nhs.uk/publication/interim-service-specification-for-specialist-gender-incongruence-services-for-children-and-young-people/

The following table shows how much the National Institute for Health and Care Research spent on research, as well as that spend as a percentage of total research spend, for gynaecological and urogynaecological, each year from 2014/15 to 2023/34, and in total over that period:

Additionally, the following table shows how much the National Institute for Health and Care Research spent on research, as well as that spend as a percentage of total research spend, for asthma, each year from 2014/15 to 2023/34, and in total over that period:

Finally, the following table shows how much the National Institute for Health and Care Research spent on research, as well as that spend as a percentage of total research spend, for diabetes, each year from 2014/15 to 2023/34, and in total over that period:

Information on the proportion of general practices commissioned to fit long-acting reversible contraception for the purposes of gynaecological care, as well as the fitting fee and cost of fitting in primary care, is not collected centrally.

The Department has invested £25 million over 2023/24 and 2024/25 to support the establishment of at least one pilot women’s health hub in every integrated care system. The 2024/25 NHS priorities and operational planning guidance asks integrated care boards (ICBs) to establish and develop at least one women’s health hub in every ICB by December 2024, working in partnership with local authorities.

NHS England has asked the ICBs to report regularly on their progress implementing the funding. As of September 2024, 36 of the 42 ICBs had had reported to NHS England that their women’s health hub was open. Those ICBs are:

• NHS Bath and North East Somerset, Swindon and Wiltshire ICB;
• NHS Bedfordshire, Luton and Milton Keynes ICB;
• NHS Birmingham and Solihull ICB;
• NHS Bristol, North Somerset and South Gloucestershire ICB;
• NHS Buckinghamshire, Oxfordshire and Berkshire West ICB;
• NHS Cheshire and Merseyside ICB;
• NHS Cornwall and The Isles Of Scilly ICB;
• NHS Coventry and Warwickshire ICB;
• NHS Derby and Derbyshire ICB;
• NHS Devon ICB;
• NHS Frimley ICB;
• NHS Gloucestershire ICB;
• NHS Greater Manchester ICB;
• NHS Hampshire and Isle of Wight ICB;
• NHS Herefordshire and Worcestershire ICB;
• NHS Hertfordshire and West Essex ICB;
• NHS Kent and Medway ICB;
• NHS Leicester, Leicestershire and Rutland ICB;
• NHS Lincolnshire ICB;
• NHS Mid and South Essex ICB;
• NHS Norfolk and Waveney ICB;
• NHS North Central London ICB;
• NHS North East and North Cumbria ICB;
• NHS North East London ICB;
• NHS North West London ICB;
• NHS Northamptonshire ICB;
• NHS Nottingham and Nottinghamshire ICB;
• NHS Shropshire, Telford and Wrekin ICB;
• NHS Somerset ICB.
• NHS South East London ICB;
• NHS South Yorkshire ICB;
• NHS Staffordshire and Stoke-on-Trent ICB;
• NHS Suffolk and North East Essex ICB;
• NHS Surrey Heartlands ICB;
• NHS Sussex ICB; and
• NHS West Yorkshire ICB.

The Birmingham, RAND, and Cambridge Evaluation, published in September 2024, identified 17 women’s health hubs in England which were established between 2001 and 2022. The report is available at the following link:

https://www.journalslibrary.nihr.ac.uk/hsdr/JYFT5036/#/abstract

The research notes the difficulty in locating models for women’s health hubs, meaning the research may not have captured all open women’s health hubs, in particular hubs that have opened more recently as locally-led initiatives.

Following referral from the Department, the National Institute for Health and Care Excellence (NICE) is currently planning the development of a guideline on the assessment and management of polycystic ovary syndrome. The NICE is exploring the possibility of collaboration with a reputable, guidance-producing partner to enhance the speed and efficiency of this work. The NICE’s website will be updated at the earliest opportunity, when expected timings are confirmed.

The information requested is not held centrally. A range of procedures are used to investigate and treat gynaecological conditions. For example, ultrasound can be used in the diagnosis of fibroids, hysteroscopy can be used to investigate symptoms such as unexplained vaginal bleeding, and laparoscopy can be used to diagnose and treat endometriosis.

The Government recognises that some procedures, such as hysteroscopy, can result in pain, and the level of pain experienced will vary between individual women. It is important that healthcare professionals provide women with information prior to their procedure so that women can make an informed decisions about the procedure and pain relief options, including the option of local or general anaesthetic.

All women with neurofibromatosis type 1 are eligible to begin screening at the age of 40 years old. This is 10 years below the normal screening age of 50 years old. Women can have screenings from a younger age if they have a higher-than-average risk of breast cancer, for example due to family history or an inherited gene such as BRCA.

We remain committed to the UK Rare Diseases Framework, which highlights helping patients get a final diagnosis faster, and improved access to specialist care, treatment, and drugs as priorities to improve the lives of people with living with rare diseases.

NHS England commissions a service for adults and children with complex neurofibromatosis type 1 (NF1). This is provided by Manchester University NHS Foundation Trust and Guy's and St Thomas' NHS Foundation Trust. The overall aim of the service is to provide the highest quality of care to people with complex NF1 through accurate diagnosis, including genetic testing, coordinated care from a specialist multidisciplinary team, monitoring of complications of the disease, and referral to other specialties as required. The two national centres and a multi-disciplinary team of senior doctors and nurses co-ordinate diagnosis and long-term care of patients with complex NF1. A referral is needed to access this service, and both centres also accept non-complex NF1 referrals. The clinicians in the complex NF1 team contribute to the evidence base on this condition, including development of international guidelines. Genetic testing for NF1 is available through the NHS Genomic Medicine Service.

The National Institute for Health and Care Excellence (NICE) has no plans to develop a guideline on NF1. With the exception of health technology evaluations, where the NICE's responsibilities are clearly defined, the NICE will not routinely produce guidelines that relate to single rare diseases. Instead, they seek to identify commonalities between conditions to provide products that can be applied across multiple rare disease groups.

NICE guidelines are developed by experts based on a thorough assessment of the available evidence, and through extensive engagement with interested parties. They describe best practice, and healthcare professionals are expected to take them fully into account in the care and treatment of their patients, although they are not mandatory and do not override a clinician’s responsibility to make decisions appropriate to individual patients.

The statement from my Rt hon. Friend, the Chancellor of the Exchequer on 29 July 2024 sets out the position across the Government, and includes departments making savings to pay towards the outcomes of the Pay Review Bodies. As the process for agreeing savings is not yet complete, at this point we cannot provide the breakdown requested.

However, the Government is committed to ensuring the National Health Service receives the funding it needs to pay for this deal. There will be no reduction in the availability or quality of frontline health and care services as a consequence of funding this pay award.

Any Barnett consequential would be provided to the devolved administrations in the usual way. Any additional funding that flows to the Department as a result would be at supplementary estimates in 2024/25.

As soon as the Foreign Secretary came into office, he commissioned new advice on Israel's compliance with International Humanitarian Law, in the context of the war. This is an important and complex process, requiring detailed analysis of evidence, and close co-operation with other Government Departments, and is being undertaken urgently. The Foreign Secretary's decision, and the Government's decision on the related issue of arms exports, will be made public when the process is complete.

The Foreign Secretary and I have publicly called for an immediate end to the violence and unrest in Bangladesh, and for all sides to find a peaceful way forward. I discussed the situation with the Bangladesh High Commissioner to London on 19 and 23 July and stressed the need for democratic freedoms and the rule of law to be protected. The British High Commissioner to Bangladesh has engaged with Bangladesh government ministers reinforcing messages on de-escalation and the need for constructive dialogue to reduce tensions. We are monitoring the situation closely and will continue to engage with counterparts.

I discussed my concerns regarding the violence in Bangladesh following protests with the Bangladesh High Commissioner to London on 19 and 23 July. The British High Commissioner has engaged with key ministers in the Bangladesh government to reinforce messages on de-escalation and the need for constructive dialogue to reduce tensions. The rights to protest, to peacefully assemble and to express different political views are rights the UK holds dear and must be protected. We will continue to raise the importance of respect for human rights and the rule of law with the Bangladesh government.